RESUMO
During the platelet release reaction beta-thromboglobulin (beta TG), platelet factor 4 (PF4) and thrombospondin (TSP) are released from the platelet into plasma and assays of these proteins can be used to monitor in vivo platelet activation. We have assessed their relative merits as markers of the in vivo platelet alpha-granule release reaction in a number of patient groups which have previously been shown to have elevated plasma beta TG and/or PF4 levels. It is concluded that in diseases or conditions not complicated by its reduced clearance, beta TG is the most sensitive marker of in vivo platelet alpha-granule release. However, the TSP assays may be the least ambiguous when monitoring the platelet alpha-granule release reaction in patients with renal failure who are undergoing haemodialysis with heparin anticoagulation. Under these circumstances plasma beta TG, but not PF4 or TSP, levels are elevated because of impaired renal catabolism, and the presence of a heparin-releasable reservoir of PF4 on the endothelium complicates the use of the PF4 assay. In liver failure none of these assays may accurately reflect platelet alpha-granule release because of impaired hepatic or renal elimination of the proteins.
Assuntos
beta-Globulinas/análise , Plaquetas/metabolismo , Glicoproteínas/análise , Fator Plaquetário 4/análise , beta-Tromboglobulina/análise , Adolescente , Adulto , Idoso , Criança , Pré-Escolar , Diabetes Mellitus/sangue , Prótese de Quadril , Humanos , Leucemia/sangue , Pessoa de Meia-Idade , Transtornos Mieloproliferativos/sangue , Radioimunoensaio/métodos , TrombospondinasAssuntos
Trombocitopenia/imunologia , Substituição de Aminoácidos/genética , Antígenos de Plaquetas Humanas/genética , Antígenos de Plaquetas Humanas/imunologia , Ensaio de Imunoadsorção Enzimática , Aconselhamento Genético , Predisposição Genética para Doença , Genótipo , Humanos , Imunoglobulina G/uso terapêutico , Recém-Nascido , Transfusão de Plaquetas , Reação em Cadeia da Polimerase , Trombocitopenia/genética , Trombocitopenia/terapiaRESUMO
BACKGROUND: The single-nucleotide polymorphism (SNP) rs5918 in the ITGB3 gene defines the human platelet antigen-1 (HPA-1) system encoding a Leu (HPA-1a) or Pro (HPA-1b) at position 33. HPA-1 antibodies are clinically the most relevant in the Caucasoid population, but detection currently requires alpha(IIb)beta3 integrin from the platelets of HPA-genotyped donors. OBJECTIVES: We set out to define the beta3 integrin domains required for HPA-1a antibody binding and produce recombinant soluble beta3 peptides for HPA-1 antibody detection. METHODS: We designed two sets (1a and 1b) of four soluble beta3 domain-deletion peptides (deltaSDL, deltabetaA, PSIHybrid, PSI), informed by crystallography studies and computer modeling. The footprints of three human HPA-1a-specific phage antibodies were defined by analyzing binding patterns to the beta3 peptides and canine platelets, and models of antibody-antigen interfaces were derived. Specificity and sensitivity for HPA-1a detection were assessed using sera from 140 cases of fetomaternal alloimmune thrombocytopenia (FMAIT). RESULTS: Fusion of recombinant proteins to calmodulin resulted in high-level expression in Drosophila S2 cells of all eight beta3 peptides. Testing of FMAIT samples indicated that deltabetaA-Leu33 is the superior peptide for HPA-1a antibody detection, with 96% sensitivity and 95% specificity. The existence of type I and II categories of HPA-1a antibodies was confirmed by the study of HPA-1a phage antibody footprints and the reactivity pattern of clinical samples with the four beta3-Leu33 peptides, but there was no correlation between antibody category and clinical severity of FMAIT. CONCLUSIONS: Soluble recombinant beta3 peptides can be used for detection of clinical HPA-1a antibodies.
Assuntos
Antígenos de Plaquetas Humanas/imunologia , Epitopos/imunologia , Integrina beta3/imunologia , Isoanticorpos/imunologia , Trombocitopenia Neonatal Aloimune/imunologia , Animais , Reações Antígeno-Anticorpo , Antígenos de Plaquetas Humanas/química , Antígenos de Plaquetas Humanas/genética , Plaquetas/metabolismo , Cães , Ensaio de Imunoadsorção Enzimática , Epitopos/química , Feminino , Humanos , Recém-Nascido , Integrina beta3/química , Integrina beta3/genética , Hemorragias Intracranianas/etiologia , Hemorragias Intracranianas/imunologia , Isoanticorpos/sangue , Isoanticorpos/química , Modelos Moleculares , Complexo Glicoproteico GPIIb-IIIa de Plaquetas/química , Complexo Glicoproteico GPIIb-IIIa de Plaquetas/imunologia , Polimorfismo de Nucleotídeo Único , Gravidez , Ligação Proteica , Conformação Proteica , Mapeamento de Interação de Proteínas , Estrutura Terciária de Proteína , Proteínas Recombinantes de Fusão/imunologia , Deleção de Sequência , Trombocitopenia Neonatal Aloimune/diagnósticoRESUMO
In red cell immunology, it has long been known that no one technique will detect all clinically significant antibodies. The same appears to be true for platelet immunology, and we highlight this fact by showing four examples of anti-human platelet antigen-1a that were not detected by the monoclonal antibody-specific immobilization of platelet antigen test, the most commonly used technique. Each antibody was found in a case of fetomaternal alloimmune thrombocytopenia in which the fetus or neonate was severely affected.
Assuntos
Antígenos de Plaquetas Humanas/imunologia , Plaquetas/imunologia , Imunoensaio/métodos , Isoanticorpos/análise , Trombocitopenia Neonatal Aloimune/diagnóstico , Antígenos de Plaquetas Humanas/sangue , Armazenamento de Sangue/métodos , Feminino , Humanos , Integrina beta3 , Isoanticorpos/efeitos adversos , Isoanticorpos/imunologia , Transfusão de Plaquetas , Gravidez , Trombocitopenia Neonatal Aloimune/sangueRESUMO
BACKGROUND AND OBJECTIVES: Fetomaternal alloimmune thrombocytopenia (FMAIT) is caused by maternal antibodies against a human platelet antigen (HPA) present on fetal, but absent from maternal platelets. We identified and characterized a case of FMAIT due to anti-HPA-1a in a mother with an HPA-1a1b genotype. MATERIALS AND METHODS: The first child of a 29-year-old mother presented with a petechial rash and a platelet count of 8 x 10(9) per l. Upon routine serological investigation, a discrepancy between the HPA-1a genotype and phenotype prompted the sequencing of the 15 exons of the ITGB3 (integrin beta3, GPIIIa and CD61) gene in the mother. RESULTS: The mother was genotypically HPA-1a1b heterozygous but phenotyped as HPA-1a negative. Sequencing of the ITGB3 exons confirmed HPA-1a1b heterozygosity, but also identified a novel single nucleotide insertion in exon 10 leading to a frameshift and premature termination at amino acid 471 of ITGB3. Maternal anti-HPA-1a was detected but with a pattern typical for a low-affinity antibody. Three transfusions of HPA-1a and -5b negative neonatal platelet concentrates were required to return to a safe platelet count. CONCLUSION: A rare ITGB3 allele was uncovered by the investigation of a severe case of alloimmune thrombocytopenia in a mother with HPA-1a antibodies who genotyped as HPA-1a1b.
Assuntos
Antígenos de Plaquetas Humanas/imunologia , Trombocitopenia Neonatal Aloimune/diagnóstico , Trombocitopenia Neonatal Aloimune/imunologia , Adulto , Sequência de Bases , Análise Mutacional de DNA , Feminino , Triagem de Portadores Genéticos/métodos , Genótipo , Humanos , Recém-Nascido , Integrina beta3 , Isoanticorpos/análise , Isoanticorpos/imunologia , Fenótipo , Transfusão de Plaquetas , Gravidez , Trombocitopenia Neonatal Aloimune/terapiaRESUMO
The Ce antigen is expressed on red cells of individuals with Rh haplotypes, R1 or CDe and r' or Cde. However, anti-Ce is rare, and only two cases of severe haemolytic disease of the newborn (HDN) caused by this antibody have been described (Malde et al., 2000; Wagner et al., 2000). We describe a woman who was found to have anti-Ce in her second pregnancy, resulting in a neonate with HDN that required exchange transfusion. She subsequently had a twin pregnancy, where both the twins were affected by severe haemolytic disease (HD) of the fetus because of anti-Ce and required repeated fetal transfusions, followed by exchange transfusions after birth. This is the first reported case of HD caused by anti-Ce requiring fetal transfusions.
Assuntos
Eritroblastose Fetal/imunologia , Glicoproteínas/imunologia , Sistema do Grupo Sanguíneo Rh-Hr/imunologia , Adulto , Transfusão de Sangue , Doenças em Gêmeos , Eritroblastose Fetal/etiologia , Eritroblastose Fetal/terapia , Feminino , Glicoproteínas/análise , Humanos , GravidezRESUMO
A study was undertaken to determine the incidence of bruising among blood donors and to analyse their response to the management of this complication. A total of 52 510 donors were bled at 476 consecutive donor sessions held by the Brentwood Centre during a 4-month period. Of these, 344 donors (0.66%) were found to have developed bruises following venepuncture. The incidence of bruising among males was 0. 35% and that among females was 0.98%. All bruised donors were managed by the Centre nursing and medical staff. One hundred and sixty-one donors informed the Centre that they were fully satisfied with the way their bruising was managed. Of 329 bruised donors who remained in the panel, 249 (75.7%) attended subsequent blood donor sessions in response to routine invitations, showing that the majority of bruised donors continued to donate blood. This response was compared with that of a control group of donors who did not develop any complications and there was no significant difference in the return rates between the two groups.
Assuntos
Doadores de Sangue , Equimose/etiologia , Flebotomia/efeitos adversos , Voluntários/estatística & dados numéricos , Adulto , Doadores de Sangue/psicologia , Doadores de Sangue/estatística & dados numéricos , Equimose/epidemiologia , Equimose/psicologia , Equimose/terapia , Inglaterra/epidemiologia , Feminino , Hematoma/epidemiologia , Hematoma/etiologia , Hematoma/psicologia , Hematoma/terapia , Humanos , Incidência , Masculino , Pessoa de Meia-Idade , Satisfação do Paciente , Voluntários/psicologiaRESUMO
Severe fetomaternal alloimmune thrombocytopenia requires urgent treatment with compatible platelet concentrates. As prompt treatment is sometimes delayed owing to the unavailability of compatible platelets, we established an accredited platelet donor panel to provide effective and timely transfusion support for fetal and neonatal therapy. After a mass screening programme of over 60,000 blood donations, 45 HPA-1a-negative donors with no antibodies to HPA, HLA, red cell antigens and granulocytes/lymphocytes, and with low titre anti-A and/or -B were accredited. All accredited donors were fully genotyped for HPA-1, -2, -3 and -5 by PCR-SSP. Ninety-one per cent of the accredited donors were also negative for HPA-5b.
Assuntos
Antígenos de Plaquetas Humanas , Doadores de Sangue , Transfusão de Plaquetas , Trombocitopenia/terapia , Feminino , Humanos , Recém-Nascido , Integrina beta3 , Plaquetoferese , Gravidez , Trombocitopenia/embriologiaRESUMO
To see whether the introduction of screening tests for post-transfusion non-A, non-B hepatitis (NANBH) in the UK would be worth while, the incidence of such hepatitis was assessed among patients receiving blood during operations at five hospitals served by the North London Blood Transfusion Centre. 387 patients, who each received blood or blood components from an average of 3 donors were followed up prospectively and blood samples were taken every 2 weeks for 3 months and then each month for a further 3 months. 229 patients also provided a sample at 12 months. All available patient and donor samples were tested for alanine aminotransferase concentrations and for antibody to hepatitis C virus (anti-HCV) by ELISA. Repeatedly anti-HCV positive samples were submitted to supplementary HCV assays. 1 of the 387 patients showed biochemical evidence of acute post-transfusion NANBH after exclusion of non-viral causes. Anti-HCV developed in this patient and the seroconversion was confirmed by recombinant immunoblot assay and polymerase chain reaction. Serum from 1 of the 8 donors whose blood he received was positive for anti-HCV by all three methods. In another patient HCV seroconversion was shown by ELISA but alanine aminotransferase concentrations remained normal throughout follow-up. His samples and those of his 2 donors were negative for HCV by the polymerase chain reaction. A third patient showed rises in alanine aminotransferase compatible with post-transfusion NANBH, but serology and polymerase chain reaction assays for HCV were negative for her samples and those of her donors. Anti-HCV reactivity likely to be false positive (negative by both confirmatory tests and no adverse effects in recipients) was seen in 6 of 1283 donors. This study, despite its being carried out in the part of the UK with the highest frequency of infectious markers in blood donations, has shown a very low incidence of post-transfusion NANBH.
Assuntos
Hepacivirus/imunologia , Anticorpos Anti-Hepatite/análise , Hepatite C/epidemiologia , Reação Transfusional , Doença Aguda , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Alanina Transaminase/sangue , Biomarcadores/sangue , Doadores de Sangue , Transfusão de Sangue/estatística & dados numéricos , Criança , Pré-Escolar , Estudos de Avaliação como Assunto , Feminino , Seguimentos , Hepatite C/sangue , Hepatite C/etiologia , Hepatite C/imunologia , Hepatite Crônica/sangue , Hepatite Crônica/epidemiologia , Hepatite Crônica/etiologia , Hepatite Crônica/imunologia , Humanos , Incidência , Lactente , Recém-Nascido , Londres/epidemiologia , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Estudos RetrospectivosRESUMO
The glycosylphosphatidylinositol-linked platelet protein CD109 carries the biallelic alloantigen system Gov. There is limited information on the incidence of Gov alloantibodies in neonatal alloimmune thrombocytopenia (NAITP), post-transfusion purpura (PTP) and platelet refractoriness. We adapted the monoclonal antibody-specific immobilization of platelet antigens (MAIPA) assay to the detection of Gov antibodies and determined their incidence in 605 archived samples (112 with HPA antibodies) referred for the aforementioned conditions. Here, we show that CD109 expression was reduced upon platelet storage in saline or by cryopreservation, but was stable when stored as whole blood or therapeutic platelet concentrate. Fourteen of the 605 samples contained Gov alloantibodies (anti-Gova, n = 10; anti-Govb, n = 4), with the majority in platelet refractoriness (n = 9) and, of the remaining five, four in NAITP and one in PTP. In seven cases, no other HPA antibodies were detected, three being NAITP cases. The incidence of Gov antibodies was significantly lower than HPA-1 system antibodies (n = 87), but equalled the number of HPA-5 system antibodies (n = 14) and outnumbered HPA-2 and -3 system antibodies (10 altogether).